These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35252267)

  • 41. Short-term effectiveness of intravitreal bevacizumab vs. ranibizumab injections for patients with polypoidal choroidal vasculopathy.
    Cho HJ; Baek JS; Lee DW; Kim CG; Kim JW
    Korean J Ophthalmol; 2012 Jun; 26(3):157-62. PubMed ID: 22670070
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab.
    Saito M; Kano M; Itagaki K; Oguchi Y; Sekiryu T
    Retina; 2014 Nov; 34(11):2192-201. PubMed ID: 25077530
    [TBL] [Abstract][Full Text] [Related]  

  • 43. One-year outcomes of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy.
    Hosokawa M; Morizane Y; Hirano M; Kimura S; Kumase F; Shiode Y; Doi S; Toshima S; Hosogi M; Fujiwara A; Mitsuhashi T; Shiraga F
    Jpn J Ophthalmol; 2017 Mar; 61(2):150-158. PubMed ID: 27928695
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Short-Term Outcomes of Switching to Ranibizumab in Polypoidal Choroidal Vasculopathy Resistant to Aflibercept Therapy.
    Jeon YJ; Kim JH; Kim JW; Kim CG
    J Clin Med; 2021 Dec; 10(24):. PubMed ID: 34945034
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of the 1-year Outcomes of Conbercept Therapy between Two Different Angiographic Subtypes of Polypoidal Choroidal Vasculopathy.
    Cheng Y; Shi X; Qu JF; Zhao MW; Li XX
    Chin Med J (Engl); 2016 Nov; 129(21):2610-2616. PubMed ID: 27779169
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Simultaneous intravitreal aflibercept and gas injections for submacular hemorrhage secondary to polypoidal choroidal vasculopathy.
    Wakabayashi T; Hara C; Shiraki A; Shiraki N; Sayanagi K; Sakimoto S; Sato S; Sakaguchi H; Nishida K
    Graefes Arch Clin Exp Ophthalmol; 2023 Jun; 261(6):1545-1552. PubMed ID: 36473986
    [TBL] [Abstract][Full Text] [Related]  

  • 47. One-Year Results of a Treat-and-Extend Regimen of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy.
    Tamachi T; Kohno T; Yamamoto M; Hirayama K; Kyo A; Ueda N; Hirabayashi M; Shiraki K; Honda S
    Ophthalmol Ther; 2020 Dec; 9(4):1069-1082. PubMed ID: 33058069
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization.
    Wang JK; Huang TL; Chang PY; Chen YT; Chang CW; Chen FT; Hsu YR; Chen YJ
    Sci Rep; 2018 Sep; 8(1):14389. PubMed ID: 30258077
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Factors associated with polyp regression after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy.
    Cho HJ; Han SY; Kim HS; Lee TG; Kim JW
    Jpn J Ophthalmol; 2015 Jan; 59(1):29-35. PubMed ID: 25373450
    [TBL] [Abstract][Full Text] [Related]  

  • 50. One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy.
    Yamamoto A; Okada AA; Kano M; Koizumi H; Saito M; Maruko I; Sekiryu T; Iida T
    Ophthalmology; 2015 Sep; 122(9):1866-72. PubMed ID: 26088619
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aflibercept therapy for polypoidal choroidal vasculopathy: short-term results of a multicentre study.
    Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T
    Br J Ophthalmol; 2015 Sep; 99(9):1284-8. PubMed ID: 25777816
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intravitreal aflibercept for submacular hemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Kim JH; Kim CG; Lee DW; Yoo SJ; Lew YJ; Cho HJ; Kim JY; Lee SH; Kim JW
    Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):107-116. PubMed ID: 31741044
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy.
    Wong IY; Shi X; Gangwani R; Zhao P; Iu LP; Li Q; Ng A; Li X
    BMC Ophthalmol; 2015 Jun; 15():66. PubMed ID: 26122636
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Visual and anatomic outcomes of aflibercept treatment in treatment-naive patients with neovascular age-related macular degeneration; real-life data over 24 months.
    Makri OE; Tsapardoni FN; Tsekouras IK; Lagogiannis AP; Chairas N; Pallikari A; Pagoulatos DD; Georgakopoulos CD
    Hell J Nucl Med; 2019; 22 Suppl 2():55-62. PubMed ID: 31802046
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy.
    Sakai T; Kato N; Kubota M; Tsuneoka H
    Graefes Arch Clin Exp Ophthalmol; 2017 Aug; 255(8):1565-1571. PubMed ID: 28601912
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intravitreal conbercept for choroidal neovascularisation secondary to pathological myopia in a real-world setting in China : Intravitreal conbercept was safe and effective in treating myopic choroidal neovascularization.
    Nie X; Wang Y; Yi H; Qiao Y
    BMC Ophthalmol; 2021 Mar; 21(1):116. PubMed ID: 33663431
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy.
    Kikushima W; Sakurada Y; Sugiyama A; Tanabe N; Kume A; Iijima H
    Graefes Arch Clin Exp Ophthalmol; 2017 Feb; 255(2):311-316. PubMed ID: 27534663
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CHOROIDAL THICKNESS AS A PROGNOSTIC FACTOR OF PHOTODYNAMIC THERAPY WITH AFLIBERCEPT OR RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Sakurada Y; Sugiyama A; Tanabe N; Kikushima W; Kume A; Iijima H
    Retina; 2017 Oct; 37(10):1866-1872. PubMed ID: 28002268
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Choroidal structure as a biomarker for visual acuity in intravitreal aflibercept therapy for polypoidal choroidal vasculopathy.
    Asano S; Azuma K; Shimizu K; Yamamoto R; Lee J; Murata H; Inoue T; Asaoka R; Obata R
    PLoS One; 2018; 13(5):e0197042. PubMed ID: 29746511
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Change in choroidal thickness after intravitreal injection for treatment of neovascular age-related macular degeneration: Ranibizumab versus aflibercept.
    Kaya F
    J Fr Ophtalmol; 2017 Dec; 40(10):832-838. PubMed ID: 29113742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.